Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 6.5% – Should You Sell?

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) traded down 6.5% on Monday . The stock traded as low as $12.28 and last traded at $12.1860. 528,467 shares traded hands during mid-day trading, a decline of 54% from the average session volume of 1,161,261 shares. The stock had previously closed at $13.03.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Chardan Capital upped their target price on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Royal Bank Of Canada decreased their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Citigroup upped their target price on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Finally, HC Wainwright upped their target price on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $31.80.

Eyepoint Pharmaceuticals Trading Up 2.1%

The business has a 50 day simple moving average of $13.28 and a two-hundred day simple moving average of $14.66. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -3.76 and a beta of 1.72.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.35 million. Research analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -3.09 EPS for the current fiscal year.

Insider Buying and Selling

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $15.00, for a total transaction of $36,555.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 5.13% of the stock is currently owned by corporate insiders.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of EYPT. KBC Group NV bought a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter worth about $29,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after buying an additional 1,358 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter worth about $76,000. Tower Research Capital LLC TRC lifted its position in shares of Eyepoint Pharmaceuticals by 218.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after buying an additional 5,967 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in shares of Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after buying an additional 794 shares during the last quarter. 99.41% of the stock is owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.